Selective p38α MAPK Inhibitors for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 Mitogen-Activated Protein Kinase (MAPK) inhibitors are poorly effective and toxic due to non-selective inhibition of p38 isoforms, leading to loss of critical counter-regulatory responses, and there is a need for selective inhibition of p38α MAPK to treat inflammatory and oncologic diseases without affecting other isoforms.
Innovation Solution
Development of compounds that selectively inhibit p38α MAPK by binding to a pocket near the ED substrate-docking site, defined by residues R49, H107, L108, and K165, which are designed to stabilize endothelial barrier function and mitigate inflammation without affecting p38β-dependent signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective p38 MAPK inhibitors are used, then broad p38 isoform inhibition is achieved, but toxicity occurs due to loss of counter-regulatory responses and inhibition of non-inflammatory isoforms
Solution Approach 1:
The patent applies local quality by designing inhibitors that selectively target specific functional sites (ED substrate-docking site and CADD pocket) on p38α MAPK while sparing other isoforms and critical regulatory pathways. This localized inhibition approach allows the drug to affect only the pathological p38α signaling responsible for inflammation while preserving counter-regulatory responses mediated by other p38 isoforms, thereby achieving therapeutic effectiveness without toxicity
Solution Approach 2:
The patent segments the p38 MAPK family inhibition into distinct selective targets. Instead of using broad-spectrum inhibitors that block all p38 isoforms, the invention divides the inhibition strategy to specifically target p38α at defined pockets (ED site and CADD pocket), separating the therapeutic effect from the toxic side effects caused by non-selective inhibition of other isoforms
2Reliability
If selective p38α MAPK inhibition is achieved through binding to ED substrate-docking site pocket, then therapeutic effectiveness is improved, but compound design complexity increases
Solution Approach 1:
The patent uses structural intermediaries and linker groups to bridge the aromatic core and the basic amine moiety, enabling the compound to simultaneously engage multiple pockets (ED substrate-docking site and CADD pocket) on p38α MAPK. These intermediary linkers (such as alkylene chains, heteroatom-containing groups) facilitate the spatial arrangement needed for selective binding without requiring overly complex molecular architectures
Solution Approach 2:
The patent employs universal structural motifs and scaffolds that can be systematically modified to generate multiple analogs with different pharmacological properties. The core structure featuring an aromatic group, basic amine, and linker represents a universal platform that can be adapted to target p38α selectively while maintaining manageable structural complexity through systematic variation of substituents
Data Source
AI summary
Compounds that inhibit p38a MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.